TCPG
BMY icon

Trivant Custom Portfolio Group’s Bristol-Myers Squibb BMY Stock Holding History

Trivant Custom Portfolio Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$12.2K – 114
2025
Q1 		$12.2K Hold
200
– – 0.01% 144
2024
Q4 		$11.3K Hold
200
– – 0.01% 148
2024
Q3 		$10.3K Buy
+200
New +$9.38K 0.01% 136

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trivant Custom Portfolio Group's BMY Position: Q2 2025 in Review

Trivant Custom Portfolio Group sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 200 shares — an estimated $12.2K sold.

Trivant Custom Portfolio Group first reported a position in BMY in Q3 2024 and held it in 3 quarters. The position peaked at $12.2K in Q1 2025. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

  • Trivant Custom Portfolio Group reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 200 Bristol-Myers Squibb shares in Q2 2025, an estimated $12.2K.
  • Trivant Custom Portfolio Group first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 3 quarters.
  • Trivant Custom Portfolio Group's Bristol-Myers Squibb position peaked at $12.2K in Q1 2025.
  • 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2025, filed 12 Aug 2025.